Propella Therapeutics Inc.
Propella is a privately held development stage company dedicated to bringing to market best-in-class drugs that utilize an active ingredient with a known mechanism of action.
Phase-3 ready CGS-200-5 is being developed to treat osteoarthritis knee pain (OAKP). PRL-02 is being developed to treat metastatic prostate cancer.
Our current pipeline encompasses brilliant new products that offer promise for highly unmet needs.
Both CGS-200-5 and PRL-02 product candidates are covered by issued US patents that are wholly-owned by Propella.